<bill session="115" type="h" number="6577" updated="2019-07-19T21:27:28Z">
  <state datetime="2018-07-26">REFERRED</state>
  <status>
    <introduced datetime="2018-07-26"/>
  </status>
  <introduced datetime="2018-07-26"/>
  <titles>
    <title type="official" as="introduced">To amend the Public Health Service Act to shorten the exclusivity period for brand name biological products from 12 to 7 years.</title>
    <title type="short" as="introduced">Price Relief, Innovation, and Competition for Essential Drugs Act</title>
    <title type="short" as="introduced">Price Relief, Innovation, and Competition for Essential Drugs Act</title>
    <title type="short" as="introduced">PRICED Act</title>
    <title type="short" as="introduced">PRICED Act</title>
    <title type="display">PRICED Act</title>
  </titles>
  <sponsor bioguide_id="S001145"/>
  <cosponsors/>
  <actions>
    <action datetime="2018-07-26">
      <text>Introduced in House</text>
    </action>
    <action datetime="2018-07-26" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2018-07-27">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee subcommittee="" code="HSIF" name="House Energy and Commerce" activity="Referral"/>
    <committee subcommittee="Health" code="HSIF14" name="House Energy and Commerce" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
  </subjects>
  <amendments/>
  <summary date="2018-07-26T04:00:00Z" status="Introduced in House">Price Relief, Innovation, and Competition for Essential Drugs Act or the PRICED Act

This bill amends the Public Health Service Act to allow biosimilars to be marketed seven years after the reference brand name biological product is licensed. Currently, brand name biological products are provided a 12-year marketing exclusivity period.

This shortened marketing exclusivity period applies only to biological products licensed by the Food and Drug Administration after enactment of this bill.</summary>
  <committee-reports/>
</bill>
